Early intervention in the treatment of rheumatoid arthritis: Focus on tocilizumab

Citations of this article
Mendeley users who have this article in their library.


Tocilizumab is a fully humanized monoclonal antibody against interleukin-6 receptors that was approved for the treatment of patients with rheumatoid arthritis (RA). Several lines of evidence, obtained both from conventional disease-modifying anti-rheumatic drugs (DMARDs) and tumor necrosis factor (TNF) inhibitors, have supported the concept of "window of opportunity" as showing that these therapies consistently work better in early disease as compared to established RA. This review addresses the question of whether a window of opportunity gained with conventional DMARDs and TNF inhibitors can also be achieved with tocilizumab. To this end, data regarding the use of tocilizumab in early RA patients are summarized. Currently available data suggest that the earlier the treatment with tocilizumab, the better the clinical outcome can be, which may have implications for various aspects of RA treatment strategies. © 2013 Yilmaz and Simsek.




Yilmaz, S., & Simsek, I. (2013). Early intervention in the treatment of rheumatoid arthritis: Focus on tocilizumab. Therapeutics and Clinical Risk Management. https://doi.org/10.2147/TCRM.S35784

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free